Indoco Remedies Plant II (Sterile) Goa Facility Receives 7 USFDA Observations

Indoco Remedies Ltd announced that its manufacturing facility at Plant II (Sterile) in Goa underwent an inspection by the United States Food and Drug Administration (USFDA) from August 27 to September 4, 2026. Following the inspection, the company received seven observations in Form 483. Indoco Remedies stated that it is comprehensively addressing these observations and will submit its response to the USFDA within the stipulated timeframe. This development is crucial as USFDA compliance is vital for exporting pharmaceutical products to the United States market.